The Therapeutics segment at Aclaris Therapeutics is dedicated to the discovery, development, and commercialization of innovative therapies targeting immuno-inflammatory diseases. This segment focuses on addressing significant unmet needs in dermatology and immunology through a pipeline of novel drug candidates. Research and development activities include preclinical studies, clinical trials, and regulatory affairs to advance potential treatments for conditions like rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and hidradenitis suppurativa. The segment leverages cutting-edge technologies and methodologies to identify and develop targeted therapies that improve patient outcomes and quality of life. Future opportunities include expanding the pipeline with new indications and strategic partnerships to accelerate drug development and market access.

The Contract Research segment provides laboratory services, supporting pharmaceutical and biotechnology companies in their research and development efforts. This segment offers a range of services, including preclinical testing, assay development, and sample analysis. Aclaris leverages its expertise and state-of-the-art facilities to deliver high-quality data and insights to its clients. The segment focuses on building strong relationships with its partners and providing customized solutions to meet their specific needs. Future opportunities include expanding the service offerings and geographic reach to capture a larger share of the growing contract research market. This segment contributes to the overall revenue and profitability of Aclaris Therapeutics while supporting the advancement of medical research and innovation.